Stifel starts Tandem Diabetes at buy
Stifel Nicolas has initiated coverage of Tandem Diabetes Care (NASDAQ:TNDM) with a “buy” rating and $30 price target, saying the company appears poised for dramatic growth with what “we view as a...
View Article
Image may be NSFW.
Clik here to view.
Clik here to view.
Feltl starts Tandem Diabetes with strong buy
Feltl & Co. has initiated coverage of Tandem Diabetes Care (NASDAQ:TNDM) with a “strong buy” rating and $19 price target. The stock closed at $14.36 on Thursday. “Tandem Diabetes entered the pump...
View Article
Image may be NSFW.
Clik here to view.
Clik here to view.
Tandem Diabetes in data partnership with Tidepool
Tandem Diabetes Care (NASDAQ:TNDM) has entered into a partnership with Tidepool, a non-profit dedicated to improving diabetes therapy management by offering an open source software platform that...
View Article
More Pages to Explore .....
